logo
About
R&D
Pipeline
Investors
News
Contact
For Patients
Primary Sclerosing Cholangitis
Nonalcoholic Steatohepatitis (NASH)
(NASH) דלקת כבד על רקע שומני
Investor Relations
Investor Relations
Overview
News & Events
News
Events
Presentations
Contact IR
Email Alerts
Financials & Filings
SEC Filings
Annual Reports
Quarterly Results
Stock
Stock Quote & Chart
Historical Stock Price
Analyst Coverage
Corporate Governance
Board Committees
Board of Directors
Leadership
Documents
News
Events
Presentations
Contact IR
Email Alerts
News
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
OK
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
OK
Email Alerts
Year
All Years
2022
2021
2020
2019
2018
2017
2016
2015
2014
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Asset Types
Photos
Video
Audio
Documents
Events
Standard
Chemomab Awarded New U.S. Patent for CM-101, Its First-in-Class CCL24 Neutralizing Antibody
June 28, 2022
Chemomab Presents Data Further Supporting the Mechanism of Action and Potential Efficacy of CM-101 in Primary Sclerosing Cholangitis
June 27, 2022
Chemomab Therapeutics Appoints Jill M. Quigley, JD, to Its Board of Directors
June 21, 2022
Chemomab Therapeutics to Present at June Investor and Scientific Conferences
June 09, 2022
Data Supporting Role of Chemomab's Novel Therapeutic Target CCL24 in Systemic Sclerosis Presented at EULAR 2022
June 02, 2022
Chemomab Therapeutics to Participate in H.C. Wainwright Global Investment Conference
May 18, 2022
Chemomab Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update
May 12, 2022
Chemomab Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update
May 04, 2022
Chemomab Therapeutics to Participate in Cantor Fitzgerald Rare Orphan Disease Summit
March 23, 2022
Chemomab Reports on Two Scientific Presentations that Support the Potential Therapeutic Utility of CM-101 in Systemic Sclerosis
March 14, 2022
Load More
Loading...